Skip to main content
Caplight Logo









DiscGenics

DiscGenics

Private
Salt Lake City, UtahHealthcare & Life Scienceshttps://www.discgenics.com/

Last Round

Series C

Aug 25, 2020

Total Funding Raised

$79.76M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

DiscGenics is a biopharmaceutical company that develops regenerative cell-based therapies to alleviate pain and restore function in patients with degenerative spinal diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicinecell therapydegenerative disc diseasebiotechrebonuputemcelIDCTallogeneic cell therapyclinical trialsorthopedic biotechnologytissue engineeringRMAT designationbiologicsspine healthoff-the-shelf therapymedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DiscGenics Comparables

Compare DiscGenics with similar companies based on industry and business-model similarity.

DiscGenics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mesoblast Limited
83%
BioRestorative Therapies, Inc.
82%
VIVEX Biologics
81%

DiscGenics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CAug 25, 2020
DebtApr 14, 2020
Series BSep 26, 2017
Series ANov 30, 2013
Series AOct 5, 2011

Key People

Founding team and executive leadership

Flagg Flanagan

Chief Executive Officer Chairman Of The Board

Executive Team

Kevin Foley

Board Member, Chief Medical Officer

Executive Team

DiscGenics Investors

Notable investors and investment history

DiscGenics investors
InvestorRounds
NT InvestmentsSeries C, Series B
Medical Incubator JapanSeries C
Mitsubishi UFJ CapitalSeries C, Series B
Ci:z Investment LLPSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors increased 144% MoM, reaching 3.8K.

  • Apr 9, 2025

    Opened a cGMP facility for scalable cell manufacturing in Salt Lake City.

DiscGenics Filings

Explore SEC and related filing metadata, where available.

DiscGenics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about DiscGenics's valuation, stock price, and market status.

Is DiscGenics a public or private company?

DiscGenics is a private company.

What is the current stock price of DiscGenics?

DiscGenics is a private company with no public stock price. No recent secondary market data is available.

How much is DiscGenics worth (valuation)?

Valuation information for DiscGenics is not publicly available.

Can I buy DiscGenics stock?

DiscGenics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was DiscGenics's last funding round?

DiscGenics's most recent funding round was Series C on August 25, 2020.

Who are the main investors in DiscGenics?

Key investors in DiscGenics include Ci:z Investment LLP.

Will DiscGenics IPO soon?

No public IPO plans have been announced for DiscGenics.

How can I track DiscGenics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DiscGenics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSalt Lake City, Utah
Employee Range33
Year Founded2008
Last FundingAug 25, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?